Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-05-22 Board/Management Inform…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 92% confidence The document is a mandatory disclosure to the Financial Services Commission and Korea Exchange concerning the appointment of an outside director (사외이사 선임). It contains details of the board change (name, term, career). This falls under announcements of changes in the company's board or management, matching the "Board/Management Information" category.
2026-05-22 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is the published results of an extraordinary shareholders’ meeting (임시주주총회 결과), detailing individual resolutions, voting outcomes, and percentages. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA), which covers official vote results at any general meeting.
2026-05-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 99% confidence The document is titled “임원ㆍ주요주주 특정증권등 소유상황보고서” filed to the Korean Securities and Futures Commission and Korea Exchange, detailing an officer’s shareholdings, changes and transactions. This is exactly an insider/director personal transaction report. Therefore it falls under Director’s Dealing (insider trades).
2026-05-20 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” and covers the period 2026-01-01 to 2026-03-31, providing detailed business description, financial tables, production capacity, R&D activities, risk management, and other substantive financial and operational disclosures. It is a full interim (quarterly) report containing actual financial statements and analysis, not merely an announcement or a link to download a report. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항 (COVID-19 예방 백신 AdCLD-CoV19-1 LP.8.1의 제2상 임상시험 계획 승인(IND) 신청 반려)
Regulatory Filings
2026-05-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-06 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.